Each project has a bespoke designed panel, addressing specific clinical hypotheses. We work directly with research teams to establish the clinical question at hand and determine how our cutting-edge techniques can support their projects. Core themes running throughout our collaborations include:

• Immune infiltration
• Molecular subtyping of disease
• AI Mediated Pathology assessments

We have also embarked on an integrative multi-omic approach with FACS and multiple sequencing modalities.

Gastro-oesophageal cancer

• ICONIC
  Collaborator: Professor Marco Gerlinger
  Project summary: The ICONIC trial is one of the first clinical trials to administer a chemo-immunotherapy combination in a peri-operative setting in gastro-oesophageal adenocarcinomas. We are studying changes of the immunological landscape before, during and after treatment to understand the impact of the treatment on the tumour cells and their microenvironment and to define predictive tools.
• FLOT-ECX
  Collaborator: Professor David Cunningham/Dr Avani Athauda
  Project summary: This tissue collection forms the paired control group to the ICONIC sample cohort. All patients were treated with standard chemotherapy regimen. We are looking into chemotherapy related changes in the tumour microenvironment and will compare the results with the findings of the ICONIC trial cohort.
• SOLAR
  Collaborator: Dr Naureen Starling/Dr Elizabeth Cartwright
  Project summary: The SOLAR clinical trial treats patients with advanced gastro-oesophageal cancers with a PARP inhibitor. We will study the molecular features of the tumour cells and changes in the tumour microenvironment to define predictive tools.
• PLATFORM
  Collaborator: Professor David Cunningham
  Project summary: This Phase III maintenance therapy trial for advanced gastro-oesophageal cancer patients comprises different treatment arm, including immunotherapy, capecitabine and trastuzumab. We are looking into morphological, molecular and immunological features of the cancers and their outcomes in different treatment arms.
• TransOG
  Collaborator: Professor David Cunningham/Dr Justin Mencel
  Project summary: This clinical trial cohort comprises three major trials in resectable gastro-oesophageal cancers (ST03, OE02, OE05) and forms one of the biggest clinical trial tissue cohort in this cancer type. We are studying molecular and immunological features to establish better predictive tools.

Other cancers

• RADIO/PLUMMB bladder cancer
  Collaborator: Dr Anna Wilkins/Professor Nick James
  Project summary: Patterns of cells/ distinct cell types in the tumour microenvironment correlate with survival outcomes in bladder cancer following radiotherapy.